Long-Term Follow-Up of Women in Trials of Adjuvant Therapy for Breast Cancer: Is It Still Important?

2011 ◽  
Vol 29 (13) ◽  
pp. 1651-1652 ◽  
Author(s):  
Kathleen I. Pritchard ◽  
Berta Sousa
The Breast ◽  
1995 ◽  
Vol 4 (3) ◽  
pp. 240-241 ◽  
Author(s):  
D.A. Cameron ◽  
E.D. Anderson ◽  
P. Levack ◽  
A.P.M. Forrest ◽  
R.C.F. Leonard ◽  
...  

2011 ◽  
Vol 29 (25) ◽  
pp. 3492-3492 ◽  
Author(s):  
Colin McCowan ◽  
John A. Dewar ◽  
Alastair M. Thompson

2004 ◽  
Vol 130 (6) ◽  
pp. 327-333 ◽  
Author(s):  
Hans Geinitz ◽  
Frank B. Zimmermann ◽  
Reinhard Thamm ◽  
Monika Keller ◽  
Raymonde Busch ◽  
...  

1991 ◽  
Vol 9 (5) ◽  
pp. 736-740 ◽  
Author(s):  
L E Spitler

We conducted a long-term follow-up (median, 10.5 years) of patients included in a randomized trial of levamisole versus placebo as surgical adjuvant therapy in 203 patients with malignant melanoma. Of the patients randomized, 104 received levamisole, and 99 received placebo. The results show that there is no difference between the treatment and control groups with regard to any of the three end points analyzed. These included disease-free interval, time to appearance of visceral metastasis, and survival. Moreover, there was no significant difference between the treatment and control groups after adjusting for age, sex, or stage of disease.


Sign in / Sign up

Export Citation Format

Share Document